Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.